angiotensin ii, des-phe(8)- has been researched along with Aortic Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, M; Gao, F; Hao, PP; Li, JJ; Liu, XL; Meng, X; Wang, XP; Yang, JM; Yang, XY; Zhang, C; Zhang, K; Zhang, MX; Zhang, Y; Zhao, XQ; Zhao, YX | 1 |
| Dong, M; Guan, J; Meng, X; Niu, R; Sun, Y; Yang, J; Yang, X; Zhang, C; Zhang, Y | 1 |
| Cao, Q; Gong, J; Liu, Y; Song, Y; Yu, M; Zhang, L | 1 |
| Casley, D; Gaspari, TA; Tesanovic, S; Vinh, A; Widdop, RE | 1 |
4 other study(ies) available for angiotensin ii, des-phe(8)- and Aortic Diseases
| Article | Year |
|---|---|
Angiotensin-(1-7) dose-dependently inhibits atherosclerotic lesion formation and enhances plaque stability by targeting vascular cells.
Topics: Angiotensin I; Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Blood Pressure; Body Weight; Cell Movement; Cell Proliferation; Collagen; Dose-Response Relationship, Drug; Lipids; Macrophages; Matrix Metalloproteinases; Mice; Mice, Knockout; Microfilament Proteins; Muscle Proteins; Muscle, Smooth, Vascular; Peptide Fragments; Receptor, Angiotensin, Type 2; RNA, Messenger; Vasodilator Agents | 2013 |
Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdominal; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cell Line; Cell Movement; Cell Proliferation; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Humans; Lipids; Losartan; Macrophages; Male; Mice, Knockout; Muscle, Smooth, Vascular; Peptide Fragments; Plaque, Atherosclerotic; Renin-Angiotensin System; Superoxides; Time Factors; Vasodilation | 2015 |
Soluble receptor for advanced glycation end products mitigates vascular dysfunction in spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Animals; Aorta; Aortic Diseases; Gene Expression Regulation, Enzymologic; Glycation End Products, Advanced; Lactoylglutathione Lyase; NF-kappa B; Oxidative Stress; Peptide Fragments; Peptidyl-Dipeptidase A; PPAR gamma; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Receptor for Advanced Glycation End Products; Vascular Remodeling | 2016 |
Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice.
Topics: Acetylcholine; Angiotensin I; Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endothelium, Vascular; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide; Nitric Oxide Synthase Type III; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyridines; Receptor, Angiotensin, Type 2; Receptors, G-Protein-Coupled; Superoxides; Time Factors; Vasodilation; Vasodilator Agents | 2010 |